Peripheral neuropathy in colorectal cancer survivors: The influence of oxaliplatin administration. Results from the population-based PROFILES registry

References

• Andre T, Boni C, Mounedji-Boudiaf L, Navarro M, Tabernero J, Hickish T, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004;350:2343–51.
   PubMed Web of Science ®Google Scholar
• Mols F, Beijers T, Lemmens V, van den Hurk CJ, Vreugdenhil G, van de Poll-Franse LV. Chemotherapy- induced neuropathy and its association with quality of life among 2- to 11-year colorectal cancer survivors: Results from the population-based PROFILES registry. J Clin Oncol 2013;31:2699–707.
   PubMed Web of Science ®Google Scholar
• Mols F, Beijers T, Vreugdenhil G, van de Poll-Franse L. Chemotherapy-induced peripheral neuropathy and its association with quality of life: A systematic review. Support Care Cancer 2014;22:2261–9.
   PubMed Web of Science ®Google Scholar
• Park SB, Lin CS, Krishnan AV, Goldstein D, Friedlander ML, Kiernan MC. Dose effects of oxaliplatin on persistent and transient Na+ conductances and the development of neurotoxicity. PLoS One 2011;6:e18469.
   PubMed Web of Science ®Google Scholar
• Faber CG, Hoeijmakers JG, Ahn HS, Cheng X, Han C, Choi JS, et al. Gain of function Nanu1.7 mutations in idiopathic small fiber neuropathy. Ann Neurol 2012;71: 26–39.
   PubMed Web of Science ®Google Scholar
• Faber CG, Lauria G, Merkies IS, Cheng X, Han C, Ahn HS, et al. Gain-of-function Nav1.8 mutations in painful neuropathy. Proc Natl Acad Sci U S A 2012;109:19444–9.
   PubMed Web of Science ®Google Scholar
• Adelsberger H, Quasthoff S, Grosskreutz J, Lepier A, Eckel F, Lersch C. The chemotherapeutic oxaliplatin alters voltage-gated Na(+) channel kinetics on rat sensory neurons. Eur J Pharmacol 2000;406:25–32.
   PubMed Web of Science ®Google Scholar
• Matsumoto S, Nishimura T, Kanai M, Mori Y, Nagayama S, Kawamura J, et al. Safety and efficacy of modified FOLFOX6 for treatment of metastatic or locally advanced colorectal cancer. A single-institution outcome study. Chemotherapy 2008;54:395–403.
   Google Scholar
• Park SB, Lin CS, Krishnan AV, Goldstein D, Friedlander ML, Kiernan MC. Long-term neuropathy after oxaliplatin treatment: Challenging the dictum of reversibility. Oncologist 2011;16:708–16.
   PubMed Web of Science ®Google Scholar
• Cavaletti G, Tredici G, Petruccioli MG, Donde E, Tredici P, Marmiroli P, et al. Effects of different schedules of oxaliplatin treatment on the peripheral nervous system of the rat. Eur J Cancer 2001;37:2457–63.
   PubMed Web of Science ®Google Scholar
• Beijers AJ, Mols F, Vreugdenhil G. A systematic review on chronic oxaliplatin-induced peripheral neuropathy and the relation with oxaliplatin administration. Support Care Cancer 2014;22:1999–2007.
   PubMed Web of Science ®Google Scholar
• van de Poll-Franse LV, Horevoorts N, van Eenbergen M, Denollet J, Roukema JA, Aaronson NK, et al. The patient reported outcomes following initial treatment and long term evaluation of survivorship registry: Scope, rationale and design of an infrastructure for the study of physical and psychosocial outcomes in cancer survivorship cohorts. Eur J Cancer 2011;47:2188–94.
   PubMed Web of Science ®Google Scholar
• Postma TJ, Aaronson NK, Heimans JJ, Muller MJ, Hildebrand JG, Delattre JY, et al. The development of an EORTC quality of life questionnaire to assess chemotherapy-induced peripheral neuropathy: The QLQ-CIPN20. Eur J Cancer 2005;41:1135–9.
   PubMed Web of Science ®Google Scholar
• Andre T, Boni C, Navarro M, Tabernero J, Hickish T, Topham C, et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol 2009;27:3109–16.
   PubMed Web of Science ®Google Scholar
• Land SR, Kopec JA, Cecchini RS, Ganz PA, Wieand HS, Colangelo LH, et al. Neurotoxicity from oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: NSABP C-07. J Clin Oncol 2007;25:2205–11.
   PubMed Web of Science ®Google Scholar
• Storey DJ, Sakala M, McLean CM, Phillips HA, Dawson LK, Wall LR, et al. Capecitabine combined with oxaliplatin (CapOx) in clinical practice: How significant is peripheral neuropathy? Ann Oncol 2010;21: 1657–61.
   PubMed Web of Science ®Google Scholar
• Schmoll HJ, Cartwright T, Tabernero J, Nowacki MP, Figer A, Maroun J, et al. Phase III trial of capecitabine plus oxaliplatin as adjuvant therapy for stage III colon cancer: A planned safety analysis in 1,864 patients. J Clin Oncol 2007;25:102–9.
   PubMed Web of Science ®Google Scholar
• Andre T, Iveson T, Labianca R, Meyerhardt JA, Souglakos I, Yoshino T, et al. The IDEA (International Duration Evaluation of Adjuvant Chemotherapy) collaboration: Prospective combined analysis of phase III trials investigating duration of adjuvant therapy with the FOLFOX (FOLFOX4 or modified FOLFOX6) or XELOX (3 versus 6 months) regimen for patients with stage III colon cancer: Trial design and current status. Curr Colorectal Cancer Rep 2013;9:261–9.
   PubMedGoogle Scholar
• Labianca R. FOLFOX-4 3 months versus 6 months and bevacizumab as adjuvant therapy for patients with stage II/III colon cancer (TOSCA). In: Gruppo Italiano per lo studio dei Carcinomi dell’Apparato Digerente 2014. [updated 2013 Sep 3; cited 2014 Jul 22]. Available from: http://www.clinicaltrials.gov/show/NCT00646607
   Google Scholar
• Argyriou AA, Velasco R, Briani C, Cavaletti G, Bruna J, Alberti P, et al. Peripheral neurotoxicity of oxaliplatin in combination with 5-fluorouracil (FOLFOX) or capecitabine (XELOX): A prospective evaluation of 150 colorectal cancer patients. Ann Oncol 2012;23:3116–22.
   PubMed Web of Science ®Google Scholar
• Ducreux M, Bennouna J, Hebbar M, Ychou M, Lledo G, Conroy T, et al. Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/leucovorin plus oxaliplatin (FOLFOX-6) as first-line treatment for metastatic colorectal cancer. Int J Cancer 2011;128:682–90.
   PubMed Web of Science ®Google Scholar
• LoPachin RM, Lehning EJ. Mechanism of calcium entry during axon injury and degeneration. Toxicol Appl Pharmacol 1997;143:233–44.
   PubMed Web of Science ®Google Scholar
• Argyriou AA, Cavaletti G, Antonacopoulou A, Genazzani AA, Briani C, Bruna J, et al. Voltage-gated sodium channel polymorphisms play a pivotal role in the development of oxaliplatin-induced peripheral neurotoxicity: Results from a prospective multicenter study. Cancer 2013;119:3570–7.
   PubMed Web of Science ®Google Scholar
• Dib-Hajj SD, Yang Y, Black JA, Waxman SG. The Na(V)1.7 sodium channel: From molecule to man. Nat Rev Neurosci 2013;14:49–62.
   PubMed Web of Science ®Google Scholar
• Zanders MM, van Steenbergen LN, Haak HR, Rutten HJ, Pruijt JF, Poortmans PM, et al. Diminishing differences in treatment between patients with colorectal cancer with and without diabetes: A population-based study. Diabet Med 2013;30:1181–8.
   PubMed Web of Science ®Google Scholar